Company intelligence / Profile preview

Trivium

Ownership: Private
Development stage: Other

Overview

TriviumVet develops novel therapeutics for companion animals with unmet medical needs. Its lead product, Felycin®–CA1 (sirolimus delayed-release tablets), received the first FDA conditional approval for treating ventricular hypertrophy due to subclinical HCM in cats. The company’s pipeline includes drugs targeting chronic kidney disease, neuropathic pain, gastric ulcers, and age-related decline—primarily using small molecule approaches including mTOR inhibitors. Recent acquisitions have enabled global commercialization partnerships.

Therapeutic areas: NephrologyImmunologyGastroenterologyCardiovascularNeurology
Modalities: Small moleculemTOR inhibitor platformProton pump inhibitor
Industry: Veterinary

Partnerships

Pegasus Laboratories/PBI-Gordon group companies—for commercialization/distribution

Beyond the preview

Go deeper on Trivium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trivium.

Explore the full profile